---
title: "Akeso (9926.HK) falls 7% in Hong Kong trading on sharp post-open slide"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296043333.md"
description: "Akeso shares fell 7.1% to HK$89.20 in Hong Kong trading, sliding more than 5% within five minutes after the open."
datetime: "2026-08-17T01:42:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296043333.md)
  - [en](https://longbridge.com/en/news/296043333.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296043333.md)
generator: "portal-rs"
---

# Akeso (9926.HK) falls 7% in Hong Kong trading on sharp post-open slide

Akeso (9926.HK) fell **7.1%** in Hong Kong trading to **HK$89.20**. The stock dropped sharply shortly after the open, sliding more than **5%** within five minutes of the opening bell, with pronounced short-term volatility.

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

- [Akeso says Phase III ivonescimab-chemo trial in biliary tract cancer meets overall survival endpoint](https://longbridge.com/en/news/297257007.md)
- [AKESO  Ivonescimab Plus Chemotherapy Phase III Study Meets Primary Overall Survival Endpoint](https://longbridge.com/en/news/296969973.md)
- [China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial](https://longbridge.com/en/news/297148879.md)
- [Ivonescimab regimen shows OS superiority in Phase III HARMONi-GI1, Summit Therapeutics notes](https://longbridge.com/en/news/297053863.md)
- [Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy](https://longbridge.com/en/news/297076262.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**